Bioverativ Inc., a leading biotechnology company headquartered in the United States, focuses on developing innovative therapies for patients with rare blood disorders, particularly haemophilia. Founded in 2017, Bioverativ has quickly established itself in the biopharmaceutical industry, achieving significant milestones such as the successful launch of its flagship products, Eloctate and Alprolix, which offer extended protection for individuals with haemophilia A and B. With a commitment to advancing treatment options, Bioverativ's unique approach combines cutting-edge science with patient-centric solutions, positioning the company as a key player in the global market. The firm operates primarily in North America and Europe, striving to improve the quality of life for those affected by these conditions. Through its dedication to research and development, Bioverativ continues to make notable contributions to the field of haemophilia care.
We don't have data for Bioverativ Inc., but we can show you information about their parent organization instead.
View parent company